Publication | Open Access

Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy

Melanoma TypeAutoimmune DiseaseMedicineMelanomaImmunologyDownstream ImplicationsImmune SurveillanceImmune Checkpoint InhibitorDermatologyImmunotherapyOncologyTumor MicroenvironmentSkin Cancer